SCHEMBL2034786

SCHEMBL2034786

N#CCc1c[nH]c2ncccc12

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 2/20 0.67
LRRK2 Q5S007 1/20 0.58
MET P08581 1/20 0.58
MTNR1A P48039 1/20 0.50
AXL P30530 1/20 0.50
DRD4 P21917 6/20 0.49
DRD2 P14416 4/20 0.49
DRD3 P35462 4/20 0.49
FGFR1 P11362 1/20 0.47
FGFR4 P22455 1/20 0.47
KMT2A Q03164 1/20 0.46
CYP1A2 P05177 2/20 0.44
CYP3A4 P08684 2/20 0.44
CYP2D6 P10635 2/20 0.44
TSHR P16473 2/20 0.44
NFKB1 P19838 2/20 0.44
HIF1A Q16665 2/20 0.44
HTR1A P08908 2/20 0.44
HTR2A P28223 2/20 0.44
HTR7 P34969 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31421790 0.84 GPR84 (0.63) GPR84LRRK2METMTNR1AAXL
SCHEMBL6219244 0.81 GPR84 (0.73) GPR84LRRK2METMTNR1AAXL
SCHEMBL27911675 0.80 GPR84 (1.00) GPR84LRRK2METMTNR1AAXL
SCHEMBL2217980 0.79 GPR84 (0.76) GPR84LRRK2METMTNR1AAXL
SCHEMBL7010590 0.77 GPR84 (0.73) GPR84LRRK2METMTNR1AAXL
SCHEMBL2692513 0.77 GPR84 (0.73) GPR84LRRK2METMTNR1AAXL
SCHEMBL7668337 0.77 GPR84 (0.73) GPR84LRRK2METMTNR1AAXL
SCHEMBL31385845 0.77 GPR84 (0.73) GPR84LRRK2METMTNR1AAXL
SCHEMBL1836680 0.77 GPR84 (0.73) GPR84LRRK2METMTNR1AAXL
SCHEMBL3934105 0.77 GPR84 (0.73) GPR84LRRK2METMTNR1AAXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12486264-B2 Bicyclic HPK1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2025-12-02 US disclosed
US-20230002394-A1 FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE AKARNA THERAPEUTICS, LTD. (GB) 2023-01-05 US disclosed
US-20220169644-A1 BICYCLIC HPK1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2022-06-02 US disclosed
EP-3177621-B1 NOVEL HDAC6 INHIBITORS AND THEIR USES UNIV REGENSBURG (DE) 2021-11-10 EP disclosed
EP-3177621-B1 NOVEL HDAC6 INHIBITORS AND THEIR USES UNIV REGENSBURG (DE) 2021-11-10 EP disclosed
US-20210214362-A1 FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE AKARNA THERAPEUTICS, LTD. (GB) 2021-07-15 US disclosed
EP-3715348-A1 FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE Akarna Therapeutics, Ltd. (GB) 2020-09-30 EP disclosed
US-10421759-B2 Fused bicyclic compounds for the treatment of disease AKARNA THERAPEUTICS, LTD. (GB) 2019-09-24 US disclosed
WO-2018213422-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS (US) 2018-11-22 WO disclosed
US-10106540-B2 HDAC6 inhibitors and their uses UNIVERSITÄT REGENSBURG (DE) 2018-10-23 US disclosed
EP-0509974-B1 Pyrrolo[2,3-b]pyridines having therapeutic activity and a process for the preparation thereof ASTRA AB (SE) 1999-01-13 EP disclosed
CN-1192202-A Diheterocyclic acrylonitriles as smooth muscle cell proliferation inhibitors AMERICAN HOME PROD (US) 1998-09-02 CN disclosed
EP-0835244-A1 DIHETEROCYCLIC ACRYLONITRILES AS SMOOTH MUSCLE CELL PROLIFERATION INHIBITORS AMERICAN HOME PRODUCTS CORPORATION (US) 1998-04-15 EP disclosed
US-5710164-A Diheterocyclic styryl nitriles AMERICAN HOME PRODUCTS CORPORATION (US) 1998-01-20 US disclosed
WO-1996039387-A1 DIHETEROCYCLIC ACRYLONITRILES AS SMOOTH MUSCLE CELL PROLIFERATION INHIBITORS AMERICAN HOME PRODUCTS CORPORATION (US) 1996-12-12 WO disclosed
US-5439917-A Phenyl-pyrrolo(2,3-b)pyridine antisecretory agent of gastric acid; adenosine triphosphatase enzyme inhibitor AKTIEBOLAGET ASTRA (SE) 1995-08-08 US disclosed
WO-1995007910-A1 ANTIVIRAL INDOLE DERIVATIVES THE WELLCOME FOUNDATION LIMITED (GB) 1995-03-23 WO disclosed
EP-0580616-A1 NEW ACTIVE COMPOUNDS Astra Aktiebolag (SE) 1994-02-02 EP disclosed
EP-0509974-A1 Pyrrolo[2,3-b]pyridines having therapeutic activity and a process for the preparation thereof Astra Aktiebolag (SE) 1992-10-21 EP disclosed
WO-1992017477-A1 NEW ACTIVE COMPOUNDS AKTIEBOLAGET ASTRA (SE) 1992-10-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10421759-B2 Fused bicyclic compounds for the treatment of disease VHL, BRDT, PAICS GPR84 3671/4885LRRK2 3117/4885MET 1156/4885
US-12486264-B2 Bicyclic HPK1 inhibitors PCK1, PGK1, PDXK GPR84 2656/4885LRRK2 877/4885MET 1628/4885
US-20220169644-A1 BICYCLIC HPK1 INHIBITORS PCK1, PGK1, PDXK GPR84 2656/4885LRRK2 877/4885MET 1628/4885
US-20230002394-A1 FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE VHL, BRDT, PAICS GPR84 3671/4885LRRK2 3117/4885MET 1156/4885
US-20210214362-A1 FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE VHL, BRDT, PAICS GPR84 3671/4885LRRK2 3117/4885MET 1156/4885
US-10106540-B2 HDAC6 inhibitors and their uses HDAC6, HDAC5, HDAC4 GPR84 2704/4885LRRK2 1842/4885MET 661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.